Multiple myeloma highlights from ASH 2025 include two late-breaking abstracts, a phase 2 trial on a novel CAR T-cell therapy, ...

Culturally congruent care and better understanding of the underlying causes are crucial to help achieve equitable treatment ...

To be accepted into a clinical trial, all potential participants must meet the "eligibility criteria" by having similar ...

Discover the latest breakthroughs in multiple myeloma treatment, including CAR T-cell therapies and promising new options for ...

Oya Gilbert, a 55-year-old who was diagnosed with multiple myeloma in 2017, encourages newly diagnosed patients, especially ...

Patient-centered care in MM involves aligning treatment with evolving quality-of-life priorities, especially during remission.

Lynozyfic (linvoseltamab), a B-cell maturation antigen and CD3 bispecific antibody, showed a high overall response rate and a ...

Experts discuss the evolving role of bispecific antibodies in multiple myeloma, highlighting treatment advancements and ...

Vyriad Inc., a Rochester-based biotech business that develops specialty viruses to fight cancers, said this week it's closed ...

Saad Usmani, MD, Chief of MSK’s Myeloma Service, says the new combination therapy could be a “big step forward for people with extramedullary myeloma.” Researchers have made great progress in the ...